Melanocortin Peptides (Bremelanotide) for Wellness
By Charles Kamen, MD, board-certified neurologist
Bremelanotide is a melanocortin peptide that improves sexual desire and arousal by acting on the brain's melanocortin pathways rather than on blood flow — the mechanism that sets it apart from every erectile-focused pill. It is FDA-approved for hypoactive sexual desire disorder (HSDD) in women, marketed as Vyleesi. [1]
Dr. Charles Kamen, MD, a board-certified neurologist at LiveNow Longevity in Las Vegas, offers melanocortin peptide therapy as part of comprehensive peptide protocols. Individual results vary.
What Is Bremelanotide (Melanocortin Peptide Therapy)?
Bremelanotide — also known as PT-141 and marketed as Vyleesi — is a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH). It acts primarily on the melanocortin 4 receptor (MC4R), a receptor in the brain involved in both sexual arousal and appetite regulation. [1]
Unlike PDE5 inhibitors such as Viagra and Cialis, which act on the vascular system to support erectile function, melanocortin peptides work through the central nervous system to enhance sexual desire and arousal at their origin — the brain rather than the blood vessels.
How Does Bremelanotide Work in the Brain?
Bremelanotide activates melanocortin receptors in the regions of the brain that govern sexual response, increasing desire and arousal through central signaling rather than through peripheral blood flow. [2]
This is where a neurologist's perspective matters. Sexual desire begins in the central nervous system, not in the genitals, so Dr. Kamen evaluates the brain-based drivers of low libido — neurological, hormonal, and psychological. A centrally acting medication only helps when the brain pathway is the actual bottleneck, which is what distinguishes melanocortin therapy from vascular-acting treatments.
Who Is a Candidate for Melanocortin Therapy?
Melanocortin therapy may be appropriate for people whose sexual concerns are driven by low desire or arousal rather than by blood flow alone — particularly when other treatments have not helped. Dr. Kamen assesses candidacy against these clinical indications:
- Hypoactive sexual desire disorder (HSDD) in men and women
- Sexual arousal difficulties that have not responded to other treatments
- Libido concerns related to age or hormonal changes
- Sexual dysfunction related to antidepressant use
What Does the Clinical Research Show?
In two randomized phase 3 trials (the RECONNECT program), bremelanotide improved sexual desire and reduced associated distress compared with placebo in women with HSDD. [3]
Clinical trials show gains in arousal, desire, and satisfaction versus placebo, though individual responses vary and depend on the underlying cause of the sexual dysfunction. Bremelanotide treats desire and arousal specifically — it is not a universal answer to every sexual concern, which is why identifying the root cause comes first.
How Is Bremelanotide Administered?
Bremelanotide is given as a subcutaneous injection, typically 30-60 minutes before anticipated sexual activity. Some patients use it on an as-needed basis; others follow a scheduled protocol. [4]
Dr. Kamen determines the most appropriate dosing based on individual response and treatment goals, and guides each patient on proper self-injection so the therapy can be used safely and comfortably at home.
What Are the Side Effects and Safety Considerations?
The most common side effects of bremelanotide are nausea, flushing, and headache, and they are usually mild and transient. Long-term safety data remain limited, so Dr. Kamen monitors for adverse effects and reassesses whether continued melanocortin therapy stays appropriate for each patient over time.
Bremelanotide may also be combined with other peptide or hormone therapies when clinically appropriate, with every combination protocol reviewed to confirm it fits the specific cause of the sexual concern and is safe.
Key Takeaways
- Bremelanotide (PT-141, marketed as Vyleesi) is a synthetic alpha-MSH analog that acts on the melanocortin 4 receptor (MC4R).
- It enhances sexual desire and arousal through central nervous system pathways — not the vascular route used by Viagra and Cialis.
- Bremelanotide is FDA-approved for hypoactive sexual desire disorder (HSDD) in women; Dr. Kamen also evaluates candidacy in men and other appropriate cases.
- Two randomized phase 3 trials (RECONNECT) showed improvements in desire and reduced distress compared with placebo.
- It is a subcutaneous injection taken 30-60 minutes before activity, either as needed or on a scheduled protocol.
- Common side effects — nausea, flushing, and headache — are usually mild and transient; long-term safety data are limited.
Common Questions
How is bremelanotide different from Viagra or Cialis?
Viagra and Cialis are PDE5 inhibitors that act on blood vessels to support erectile function. Bremelanotide works in the central nervous system, on the brain's melanocortin pathways, to increase sexual desire and arousal. They target different steps — blood flow versus desire — so they address different underlying problems.
Does bremelanotide work for women?
Yes. Bremelanotide is FDA-approved for hypoactive sexual desire disorder in women, where it is marketed as Vyleesi. In two randomized phase 3 trials, it improved desire and reduced distress compared with placebo. Dr. Kamen offers melanocortin therapy for women who are appropriate candidates after a full evaluation.
Why would a neurologist treat low libido?
Because sexual desire originates in the brain, not the genitals. As a board-certified neurologist, Dr. Kamen assesses the neurological, hormonal, and psychological drivers of low libido. A centrally acting peptide like bremelanotide only helps when the brain-based arousal pathway is the real bottleneck, which is why accurate diagnosis comes first.
What are the side effects of bremelanotide?
The most common side effects are nausea, flushing, and headache, and they are usually mild and transient. Long-term safety data remain limited, so Dr. Kamen monitors for adverse effects and reassesses whether continued melanocortin therapy stays appropriate for each patient over time.
How is bremelanotide taken, and how often?
Bremelanotide is a subcutaneous injection, typically given 30 to 60 minutes before anticipated sexual activity. Some patients use it only as needed, while others follow a scheduled protocol. Dosing frequency depends on individual response and goals, and Dr. Kamen establishes the right schedule for each patient.
Can bremelanotide be combined with other therapies?
Yes, when clinically appropriate. Bremelanotide can be combined with other peptide or hormone therapies as part of a broader plan. Dr. Kamen reviews each case to ensure safe combination protocols and to confirm that a centrally acting melanocortin peptide fits the specific cause of the sexual concern.
Bremelanotide offers a distinct, brain-based approach to low sexual desire and arousal — addressing the central pathway that erectile medications never touch. Consult with Dr. Kamen to determine whether melanocortin peptide therapy is appropriate for your situation.
References
- Dhillon S, Keam SJ. Drugs. 2019;79(14):1599-1606. (Bremelanotide: First Approval).
- Molinoff PB, et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102.
- Kingsberg SA, Clayton AH, Portman D, et al. Obstet Gynecol. 2019;134(5):899-908. (Bremelanotide for hypoactive sexual desire disorder: two randomized phase 3 trials, RECONNECT).
- Krychman M, et al. J Sex Med. 2025;22(5):746-754.
Wondering what’s right for you?
Get a straight answer from board-certified neurologist Dr. Charles Kamen, MD. The evaluation is $88 and is applied toward your protocol if you continue care.